TAIANA, ELISA
TAIANA, ELISA
Dipartimento di Oncologia ed Emato-Oncologia
The pleiotropic nature of NONO, a master regulator of essential biological pathways in cancers
2024 D. Ronchetti, V. Traini, I. Silvestris, G. Fabbiano, F. Passamonti, N. Bolli, E. Taiana
Inference of genomic lesions from single-cell RNA-seq in myeloma improves functional intraclonal and interclonal analysis
2024 F. Lazzaroni, A. Matera, A. Marella, A. Maeda, G. Castellano, A. Marchetti, S. Fabris, S. Pioggia, I. Silvestris, D. Ronchetti, S. Lonati, G. Fabbiano, V. Traini, E. Taiana, L. Porretti, F. Colombo, C. De Magistris, M. Scopetti, M. Barbieri, L. Pettine, F. Torricelli, A. Neri, F. Passamonti, M. Lionetti, M.C. Da Vià, N. Bolli
Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins
2023 E. Taiana, C. Bandini, V.K. Favasuli, D. Ronchetti, I. Silvestris, N. Puccio, K. Todoerti, S. Erratico, D. Giannandrea, N. Bolli, N. Amodio, A. Ciarrocchi, R. Chiaramonte, Y. Torrente, R. Piva, A. Neri
Molecular Modelling of NONO and SFPQ Dimerization Process and RNA Recognition Mechanism
2022 T. Laurenzi, L. Palazzolo, E. Taiana, S. Saporiti, O. Ben Mariem, U. Guerrini, A. Neri, I. Eberini
Expression levels of NONO, a nuclear protein primarily involved in paraspeckles function, are associated with several deregulated molecular pathways and poor clinical outcome in multiple myeloma
2022 D. Ronchetti, V.K. Favasuli, I. Silvestris, K. Todoerti, F. Torricelli, N. Bolli, A. Ciarrocchi, E. Taiana, A. Neri
Single-Cell RNA Sequencing for the Detection of Clonotypic V(D)J Rearrangements in Multiple Myeloma
2022 A. Matera, A. Marella, A. Maeda, M.C. Da Via, F. Lazzaroni, S. Fabris, S. Pioggia, L. Porretti, F. Colombo, F. Torricelli, A. Neri, E. Taiana, G. Fabbiano, V. Traini, E. Genuardi, D. Drandi, N. Bolli, M. Lionetti
Epigenetic Regulation of Mitochondrial Quality Control Genes in Multiple Myeloma: A Sequenom MassARRAY Pilot Investigation on HMCLs
2021 P. D'Aquila, D. Ronchetti, M.E. Gallo Cantafio, K. Todoerti, E. Taiana, F. Fabiani, A. Montesanto, A. Neri, G. Passarino, G. Viglietto, D. Bellizzi, N. Amodio
CRISPR Interference (CRISPRi) and CRISPR Activation (CRISPRa) to Explore the Oncogenic lncRNA Network
2021 E. Morelli, A. Gulla', N. Amodio, E. Taiana, A. Neri, M. Fulciniti, N.C. Munshi
Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?
2021 P. Menichini, P. Monti, A. Speciale, G. Cutrona, S. Matis, F. Fais, E. Taiana, A. Neri, R. Bomben, M. Gentile, V. Gattei, M. Ferrarini, F. Morabito, G. Fronza
Bioinformatics Pipeline to Analyze lncRNA Arrays
2021 K. Todoerti, D. Ronchetti, M. Manzoni, E. Taiana, A. Neri, L. Agnelli
In Vitro Silencing of lncRNAs Using LNA GapmeRs
2021 E. Taiana, V. Favasuli, D. Ronchetti, E. Morelli, P. Tassone, G. Viglietto, N.C. Munshi, A. Neri, N. Amodio
Transcriptomic analysis in multiple myeloma and primary plasma cell leukemia with t(11;14) reveals different expression patterns with biological implications in venetoclax sensitivity
2021 K. Todoerti, E. Taiana, N. Puccio, V. Favasuli, M. Lionetti, I. Silvestris, M. Gentile, P. Musto, F. Morabito, U. Gianelli, N. Bolli, L. Baldini, A. Neri, D. Ronchetti
The landscape of signaling pathways and proteasome inhibitors combinations in multiple myeloma
2021 T. Paradzik, C. Bandini, E. Mereu, M. Labrador, E. Taiana, N. Amodio, A. Neri, R. Piva
DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome
2021 K. Todoerti, D. Ronchetti, V. Favasuli, F. Maura, F. Morabito, N. Bolli, E. Taiana, A. Neri
Genomic instability in multiple myeloma: A “non‐coding rna” perspective
2021 E. Taiana, M.E.G. Cantafio, V.K. Favasuli, C. Bandini, G. Viglietto, R. Piva, A. Neri, N. Amodio
Dissecting the biological relevance and clinical impact of lncrna miat in multiple myeloma
2021 K. Todoerti, D. Ronchetti, N. Puccio, I. Silvestris, V. Favasuli, N. Amodio, M. Gentile, F. Morabito, A. Neri, E. Taiana
Jagged ligands enhance the pro-angiogenic activity of multiple myeloma cells
2020 M.T. Palano, D. Giannandrea, N. Platonova, G. Gaudenzi, M. Falleni, D. Tosi, E. Lesma, V. Citro, M. Colombo, I. Saltarella, R. Ria, N. Amodio, E. Taiana, A. Neri, G. Vitale, R. Chiaramonte
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma
2020 E. Taiana, V. Favasuli, D. Ronchetti, K. Todoerti, F. Pelizzoni, M. Manzoni, M. Barbieri, S. Fabris, I. Silvestris, M.E. Gallo Cantafio, N. Platonova, V. Zuccalà, L. Maltese, D. Soncini, S. Ruberti, M. Cea, R. Chiaramonte, N. Amodio, P. Tassone, L. Agnelli, A. Neri
Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance
2020 M. Colombo, S. Garavelli, M. Mazzola, N. Platonova, D. Giannandrea, R. Colella, L. Apicella, M. Lancellotti, E. Lesma, S. Ancona, M.T. Palano, M. Barbieri, E. Taiana, E. Lazzari, A. Basile, M. Turrini, A. Pistocchi, A. Neri, R. Chiaramonte
Jagged ligands as new targets in multiple myeloma associated angiogenesis
2020 D. Giannandrea, M.T. Palano, N. Platonova, G. Gaudenzi, M. Falleni, D. Tosi, E. Lesma, V. Citro, M. Colombo, I. Saltarella, R. Ria, N. Amodio, E. Taiana, A. Neri, G. Vitale, R. Chiaramonte